- Home
- CMPS vs SOPH Comparison
CMPS vs SOPH Comparison
Compare CMPS & SOPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMPS
- SOPH
- Stock Information
- Founded
- CMPS 2020
- SOPH 2011
- Country
- CMPS United Kingdom
- SOPH Switzerland
- Employees
- CMPS N/A
- SOPH N/A
- Industry
- CMPS Biotechnology: Pharmaceutical Preparations
- SOPH Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CMPS Health Care
- SOPH Health Care
- Exchange
- CMPS Nasdaq
- SOPH Nasdaq
- Market Cap
- CMPS 280.2M
- SOPH 226.6M
- IPO Year
- CMPS 2020
- SOPH 2021
- Fundamental
- Price
- CMPS $4.00
- SOPH $3.26
- Analyst Decision
- CMPS Strong Buy
- SOPH Strong Buy
- Analyst Count
- CMPS 6
- SOPH 3
- Target Price
- CMPS $33.60
- SOPH $7.00
- AVG Volume (30 Days)
- CMPS 705.9K
- SOPH 21.3K
- Earning Date
- CMPS 10-31-2024
- SOPH 11-05-2024
- Dividend Yield
- CMPS N/A
- SOPH N/A
- EPS Growth
- CMPS N/A
- SOPH N/A
- EPS
- CMPS N/A
- SOPH N/A
- Revenue
- CMPS N/A
- SOPH $64,488,000.00
- Revenue This Year
- CMPS N/A
- SOPH $7.20
- Revenue Next Year
- CMPS N/A
- SOPH $15.71
- P/E Ratio
- CMPS N/A
- SOPH N/A
- Revenue Growth
- CMPS N/A
- SOPH 9.85
- 52 Week Low
- CMPS $3.86
- SOPH $2.70
- 52 Week High
- CMPS $12.75
- SOPH $7.37
- Technical
- Relative Strength Index (RSI)
- CMPS 37.40
- SOPH 46.64
- Support Level
- CMPS $3.86
- SOPH $3.06
- Resistance Level
- CMPS $4.91
- SOPH $3.47
- Average True Range (ATR)
- CMPS 0.28
- SOPH 0.18
- MACD
- CMPS -0.01
- SOPH -0.00
- Stochastic Oscillator
- CMPS 16.59
- SOPH 45.45
About CMPS COMPASS Pathways Plc American Depository Shares
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find better ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.
About SOPH SOPHiA GENETICS SA
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.